Program
cemiplimab
Also written as “Cemiplimab”, “REGN2810” and “REGN2810/chemo/ipi”.
Its studies are mostly in Carcinoma, Non-Small-Cell Lung · Melanoma · Carcinoma, Basal Cell · Squamous Cell Carcinoma of Head and Neck · Neoplasm Metastasis, led by 7 companies.
Drug pageCemiplimab: every studyMany companies study it; this page follows only the 42 they lead. All 135 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Regeneron Pharmaceuticalsits history only | 3516 open or running | phase 3since Mar 3, 2017 | Feb 2, 2015 | Mar 22, 2027phase 3 · NCT06246916 |
| BioNTechits history only | 20 open or running | phase 2since Apr 21, 2020 | Apr 21, 2020 | none ahead |
| Maia Biotechnologyits history only | 11 open or running | phase 3since Mar 20, 2025 | Mar 20, 2025 | Jul 31, 2027phase 3 · NCT06908304 |
| Merck KGaA, Darmstadt, Germanyits history only | 10 open or running | phase 2since May 22, 2023 | May 22, 2023 | none ahead |
| Sanofiits history only | 10 open or running | phase 2since Jun 19, 2017 | Jun 19, 2017 | none ahead |
| SillaJenits history only | 10 open or running | phase 2since Sep 19, 2017 | Sep 19, 2017 | none ahead |
| Vyriadits history only | 11 open or running | phase 2since Feb 25, 2020 | Feb 25, 2020 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of every company. Pick one to see its own:
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
Not listed one by one: 29 earlier studies, Feb 2, 2015 to Jan 24, 2022.
- Jun 9, 2018Named cemiplimabINNProposed as its International Nonproprietary Name in WHO's List 119 · before, REGN2810
- Sep 23, 2022Phase 2 study in Advanced Non-Small Cell Lung CancerRegeneron Pharmaceuticals · NCT05557591 · 51 enrolled · United States, Georgia, Germany and more
- May 22, 2023Merck KGaA, Darmstadt, Germany’s first study: phase 2 study in Carcinoma, Non-Small-Cell LungNew to Merck KGaA, Darmstadt, GermanyMerck KGaA, Darmstadt, Germany · NCT05882734 · 61 enrolled · United States, Belgium, France and more
- Nov 9, 2023Phase 2 study in MelanomaRegeneron Pharmaceuticals · NCT06190951 · 151 enrolled · United States, Australia, Austria and more
- Jan 30, 2024Phase 3 study in MelanomaRegeneron Pharmaceuticals · NCT06246916 · 560 planned · United States, Canada
- Apr 22, 2024Phase 2 study in Cutaneous Squamous Cell CarcinomaRegeneron Pharmaceuticals · NCT06384820
- May 9, 2024Phase 2 study in MelanomaRegeneron Pharmaceuticals · NCT06413680 · 240 planned · United States
- Jun 6, 2024Phase 1 study in Carcinoma, Ovarian EpithelialRegeneron Pharmaceuticals · NCT06469281 · 90 planned · United States
- Sep 3, 2024Phase 3 study in Skin NeoplasmsRegeneron Pharmaceuticals · NCT06585410 · 369 planned · United States, Australia
- Jan 6, 2025Phase 2 study in Squamous Cell Carcinoma of Head and NeckRegeneron Pharmaceuticals · NCT06769698 · 120 planned · United States, Australia, France and more
- Feb 24, 2025Phase 2 study in MelanomaRegeneron Pharmaceuticals · NCT06848088 · 28 enrolled · United States, Ireland
- Mar 20, 2025Maia Biotechnology’s first study: phase 3 study in Carcinoma, Non-Small-Cell LungNew to Maia BiotechnologyMaia Biotechnology · NCT06908304 · 300 planned · Poland, Romania, Taiwan and more
- Apr 28, 2026Phase 2 study in GliomaRegeneron Pharmaceuticals · NCT07567469 · 120 planned
- Sep 1, 2026Phase 2 study in Skin NeoplasmsRegeneron Pharmaceuticals · NCT07808515 · 135 planned
- Nov 10, 2026Primary completion moved from 2029-10-10 to 2030-10-09Date moved laterphase 2 · +12 months · NCT06848088
Ahead
- Nov 2, 2026Primary completion: phase 2 study in MelanomaRegeneron Pharmaceuticals · NCT06190951
- Nov 13, 2026Primary completion: phase 2 study in Advanced Solid TumorsRegeneron Pharmaceuticals · NCT04626635
- Mar 22, 2027Primary completion: phase 3 study in MelanomaRegeneron Pharmaceuticals · NCT06246916
- Apr 29, 2027Primary completion: phase 1 study in Neoplasm MetastasisRegeneron Pharmaceuticals · NCT05259709
TargetBeta
“Programmed cell death protein 1 inhibitor”ChEMBL 37, by rule
Other programs on PDCD1
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| ivonescimabrule | Akeso | phase 3 | 48 |
| rilvegostomig | AstraZeneca | phase 3 | 24 |
| Iparomlimab/Tuvonralimabrule | Qilu Pharmaceutical | phase 3 | 22 |
| volrustomig | AstraZeneca | phase 3 | 19 |
| tivunatamig | Pfizer | phase 3 | 15 |
| nilvanstomigrule | Suzhou Zelgen Biopharmaceuticals | phase 3 | 15 |
| pucotenlimabrule | taizhou-hanzhong-biomedical-co-ltd | phase 3 | 15 |
| enlonstobartrule | CSPC Pharmaceutical Group | phase 3 | 15 |
| ezabenlimab | Boehringer Ingelheim | phase 3 | 13 |
| Anti-PD-1/IL-2 Bispecific Antibody Fusion Protein IBI363rule | Innovent Biologics | phase 3 | 10 |
| rulonilimabrule | Lunan Pharmaceutical Group | phase 3 | 9 |
| Anti-PD-1/Anti-TGF-beta Bifunctional Fusion Protein TQB2868 | Sino Biopharmaceutical | phase 3 | 4 |
Studies
All 42 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07808515Skin Neoplasms | 2 | Not yet recruiting | Regeneron Pharmaceuticals | Nov 13, 2030 | 135 |
| NCT07567469Glioma | 2 | Not yet recruiting | Regeneron Pharmaceuticals | Aug 27, 2032 | 120 |
| NCT06908304Carcinoma, Non-Small-Cell Lung · Poland, Romania, Taiwan and more | 3 | Recruiting | Maia Biotechnology | Jul 31, 2027 | 300 |
| NCT06848088Melanoma · United States, Ireland | 2 | Active, not recruiting | Regeneron Pharmaceuticals | Oct 9, 2030 | 28 |
| NCT06769698Squamous Cell Carcinoma of Head and Neck · United States, Australia, France and more | 2 | Recruiting | Regeneron Pharmaceuticals | Jun 4, 2028 | 120 |
| NCT06585410Skin Neoplasms · United States, Australia | 3 | Recruiting | Regeneron Pharmaceuticals | May 3, 2030 | 369 |
| NCT06469281Carcinoma, Ovarian Epithelial · United States | 1 | Recruiting | Regeneron Pharmaceuticals | May 27, 2030 | 90 |
| NCT06413680Melanoma · United States | 2 | Recruiting | Regeneron Pharmaceuticals | Feb 3, 2030 | 240 |
| NCT06384820Cutaneous Squamous Cell Carcinoma | 2 | Withdrawn | Regeneron Pharmaceuticals | Jun 8, 2026 | 0 |
| NCT06246916Melanoma · United States, Canada | 3 | Recruiting | Regeneron Pharmaceuticals | Mar 22, 2027 | 560 |
| NCT06190951Melanoma · United States, Australia, Austria and more | 2 | Active, not recruiting | Regeneron Pharmaceuticals | Nov 2, 2026 | 151 |
| NCT05882734Carcinoma, Non-Small-Cell Lung · United States, Belgium, France and more | 2 | Completed | Merck KGaA, Darmstadt, Germany | Jul 15, 2026 | 61 |
| NCT05557591Advanced Non-Small Cell Lung Cancer · United States, Georgia, Germany and more | 2 | Active, not recruiting | Regeneron Pharmaceuticals | Jan 26, 2028 | 51 |
| NCT05259709Neoplasm Metastasis · Netherlands | 1 | Active, not recruiting | Regeneron Pharmaceuticals | Apr 29, 2027 | 22 |
| NCT04626635Advanced Solid Tumors · United States, France, Israel and more | 2 | Active, not recruiting | Regeneron Pharmaceuticals | Nov 13, 2026 | 548 |
| NCT04526899Melanoma · United States, Australia, Germany and more | 2 | Completed | BioNTech | Jan 25, 2024 | 184 |
| NCT04382898Prostatic Neoplasms · United States, Germany, Hungary and more | 2 | Terminated | BioNTech | Jan 23, 2024 | 75 |
| NCT04373083Hodgkin Disease | 2 | Withdrawn | Regeneron Pharmaceuticals | Dec 20, 2022 | 0 |
| NCT04291105Melanoma · United States, Brazil | 2 | Active, not recruiting | Vyriad | Oct 2026 | 87 |
| NCT04154943Cutaneous Squamous Cell Carcinoma · United States, Australia, Germany | 2 | Completed | Regeneron Pharmaceuticals | Dec 1, 2021 | 79 |
| NCT03969004Cutaneous Squamous Cell Carcinoma · United States, Australia, Belgium and more | 3 | Active, not recruiting | Regeneron Pharmaceuticals | Jan 7, 2028 | 415 |
| NCT03916627Carcinoma, Non-Small-Cell Lung · United States | 2 | Active, not recruiting | Regeneron Pharmaceuticals | Mar 31, 2025 | 65 |
| NCT03889912Carcinoma, Basal Cell · United States, Australia, Netherlands | 1 | Completed | Regeneron Pharmaceuticals | Nov 13, 2025 | 97 |
| NCT03690869Central Nervous System Neoplasms · United States | 2 | Terminated | Regeneron Pharmaceuticals | May 10, 2023 | 57 |
| NCT03580694Carcinoma, Non-Small-Cell Lung · United States | 1 | Terminated | Regeneron Pharmaceuticals | Dec 4, 2019 | 17 |
| NCT03564340Ovarian Neoplasms · United States, Australia, Belgium and more | 2 | Recruiting | Regeneron Pharmaceuticals | May 10, 2027 | 890 |
| NCT03515629Carcinoma, Non-Small-Cell Lung · United States, Italy, Lithuania | 3 | Terminated | Regeneron Pharmaceuticals | Jul 29, 2021 | 5 |
| NCT03430063Advanced Non-Small Cell Lung Carcinoma · United States, Belgium, France and more | 2 | Terminated | Regeneron Pharmaceuticals | Oct 27, 2021 | 28 |
| NCT03409614Carcinoma, Non-Small-Cell Lung · United States, Austria, China and more | 3 | Completed | Regeneron Pharmaceuticals | Feb 27, 2025 | 789 |
| NCT03294083Carcinoma, Renal Cell · United States, Australia, South Korea | 2 | Completed | SillaJen | Feb 16, 2023 | 95 |
| NCT03257267Carcinoma, Squamous Cell · United States, Australia, Belgium and more | 3 | Completed | Regeneron Pharmaceuticals | Mar 15, 2021 | 608 |
| NCT03233139Advanced Malignancies · Japan | 1 | Active, not recruiting | Regeneron Pharmaceuticals | Sep 30, 2027 | 146 |
| NCT03198130Recurrent Squamous Cell Carcinoma of Head · Korea, Republic of, United Kingdom | 1 | Completed | Regeneron Pharmaceuticals | Jun 27, 2019 | 33 |
| NCT03194867Multiple Myeloma · United States, Australia, Brazil and more | 2 | Completed | Sanofi | Apr 5, 2023 | 109 |
| NCT03132636Carcinoma, Basal Cell · United States, Austria, Belgium and more | 2 | Completed | Regeneron Pharmaceuticals | May 20, 2021 | 138 |
| NCT03088540Carcinoma, Non-Small-Cell Lung · Australia, Belarus, Brazil and more | 3 | Completed | Regeneron Pharmaceuticals | Apr 18, 2025 | 712 |
| NCT03002376Melanoma · Korea, Republic of, Netherlands, Serbia and more | 1 | Completed | Regeneron Pharmaceuticals | Mar 5, 2019 | 47 |
| NCT03005782Neoplasms · United States, Australia, Ireland and more | 1 | Completed | Regeneron Pharmaceuticals | Apr 2, 2024 | 333 |
| NCT02760498Advanced Cutaneous Squamous Cell Carcinoma · United States, Australia, Brazil and more | 2 | Completed | Regeneron Pharmaceuticals | Oct 18, 2023 | 432 |
| NCT02651662Recurrence · United States, Austria, Germany and more | 1 | Completed | Regeneron Pharmaceuticals | Apr 29, 2026 | 105 |
| NCT02520245Advanced Malignancies · United States | 1 | Withdrawn | Regeneron Pharmaceuticals | Nov 2023 | 0 |
| NCT02383212Advanced Cancer · United States, Australia, Spain | 1 | Completed | Regeneron Pharmaceuticals | Nov 18, 2019 | 398 |
How it is read
Names in the registry
- “Cemiplimab”, 23 entries
- “cemiplimab”, 9 entries
- “REGN2810”, 4 entries
- “REGN2810/chemo/ipi”, 2 entries
- “Fianlimab+cemiplimab”, 1 entry
Conditions, from the studies’ own filings
- Carcinoma, Non-Small-Cell Lung, 9 studies
- Melanoma, 7 studies
- Carcinoma, Basal Cell, 3 studies
- Squamous Cell Carcinoma of Head and Neck, 1 study
- Neoplasm Metastasis, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.